CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
CareDx NASDAQ: CDNA executives outlined the company's growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration.
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing
CDNA unveils AlloSeq Nano, delivering high-resolution HLA typing in under 3 hours, aiming to boost transplant diagnostics speed and lab efficiency.
All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA
Bamco Inc. NY grew its stake in shares of CareDx, Inc. (NASDAQ: CDNA) by 29.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,155,180 shares of the company's stock after buying an additional 719,523 shares during the period. Bamco
CareDx Introduces VANTx AI Platform for Complex Transplant Datasets
CDNA launches VANTx, an AI-driven cloud platform that turns complex transplant datasets into insights to support clinical research and real-world evidence.
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) Q4 Earnings Miss Estimates
CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell therapy markets.
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript
